501-75-7

Basic information

• Product Name: 2-(1-methylimidazol-4-yl)ethanamine
• Synonyms: 2-(1-methylimidazol-4-yl)ethanamine;tele-methylhistamine;1-Methyl-1H-imidazole-4-ethanamine;4-(2-Aminoethyl)-1-methyl-1H-imidazole;N1-Methylhistamine;1-methyl-4-(2-aminoethyl)imidazole;4-(1-aminoethyl)-1-methyl-1H-imidazole;N(T)-methylhistamine
• CAS NO: 501-75-7
• Molecular Formula: C₆H₁₁N₃
• Molecular Weight: 125.1716
• Mol File: 501-75-7.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 296.7 °C at 760 mmHg
• Flash Point: 133.2 °C
• Appearance: /
• Density: 1.11 g/cm³
• PKA: 9.27±0.10(Predicted)
• CAS DataBase Reference: 2-(1-methylimidazol-4-yl)ethanamine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(1-methylimidazol-4-yl)ethanamine(501-75-7)
• EPA Substance Registry System: 2-(1-methylimidazol-4-yl)ethanamine(501-75-7)

Safety Data

• Hazardous Substances Data: 501-75-7(Hazardous Substances Data)

Usage

Uses

2-(1-methyl-1H-imidazol-4-yl)ethan-1-amine (cas# 501-75-7) is used in high fiber diets, promoting gluconeogenesis and inhibit glycolysis in muscle.

Definition

ChEBI: A primary amino compound that is the Ntau-methyl derivative of histamine.

Upstream product

• 41065-00-3 1-Methyl-4-cyanomethyl-imidazol 
• 673-49-4 N-acetylhistamine 
• 77-78-1 dimethyl sulfate 
• 51720-37-7 2-methyl-5-oxo-5,6,7,8-tetrahydroimidazo<1,5-c>pyrimidinium iodide 
• 51-45-6 histamine 
• 14509-66-1 5,6,7,8-tetrahydro-5-oxoimidazo[1,5-c]pyrimidine 
• 51-45-6 histamine 
• 18502-05-1 4-cyanomethylimidazole 

Downstream Products

• 64403-25-4 3-methyl-3,4,6,7-tetrahydro-5H-imidazo<4,5-c>pyridine 
• 58177-25-6 4-hydroxyethyl-1-methyl-1H-imidazole 
• 210238-13-4 (2R,3R,4S,5R)-2-{6-Benzylamino-2-[2-(1-methyl-1H-imidazol-4-yl)-ethylamino]-purin-9-yl}-5-(2-methyl-2H-tetrazol-5-yl)-tetrahydro-furan-3,4-diol Formate 
• 210238-69-0 (2R,3R,4S,5R)-2-{6-Benzylamino-2-[2-(1-methyl-1H-imidazol-4-yl)-ethylamino]-purin-9-yl}-5-(2-isopropyl-2H-tetrazol-5-yl)-tetrahydro-furan-3,4-diol Formate 
• 210238-07-6 (2R,3R,4S,5R)-2-{6-(2,2-Diphenyl-ethylamino)-2-[2-(1-methyl-1H-imidazol-4-yl)-ethylamino]-purin-9-yl}-5-(2-methyl-2H-tetrazol-5-yl)-tetrahydro-furan-3,4-diol Formate 
• 210238-21-4 (2R,3R,4S,5R)-2-{2-[2-(1-Methyl-1H-imidazol-4-yl)-ethylamino]-6-phenethylamino-purin-9-yl}-5-(2-methyl-2H-tetrazol-5-yl)-tetrahydro-furan-3,4-diol Formate 
• 210238-15-6 (2R,3R,4S,5R)-2-{6-(2-Cyclohexyl-ethylamino)-2-[2-(1-methyl-1H-imidazol-4-yl)-ethylamino]-purin-9-yl}-5-(2-methyl-2H-tetrazol-5-yl)-tetrahydro-furan-3,4-diol Formate 
• 210238-11-2 (2R,3R,4S,5R)-2-{6-(3-Iodo-benzylamino)-2-[2-(1-methyl-1H-imidazol-4-yl)-ethylamino]-purin-9-yl}-5-(2-methyl-2H-tetrazol-5-yl)-tetrahydro-furan-3,4-diol Formate 
• 1225591-15-0 1-[(R)-2-(4-butyryl-4-cyclohexylpiperidin-1-yl)-1-(4-methoxybenzyl)-2-oxoethyl]-3-[2-(1-methyl-1H-imidazol-4-yl)ethyl]urea 
• 1419868-80-6 C₃₁H₃₅N₇O₃ 

Relevant articles and documents

-

-

2-(1H-Imidazol-4-yl)ethanamine and 2-(1H-pyrazol-1-yl)ethanamine side chain variants of the IGF-1R inhibitor BMS-536924

A series of IGF-1R inhibitors is disclosed, wherein the (m-chlorophenyl)ethanol side chain of BMS-536924 (1) is replaced with a series of 2-(1H-imidazol-4-yl)ethanamine and 2-(1H-pyrazol-1-yl)ethanamine side chains. Some analogs show improved IGF-1R poten

CXCR4 chemokine receptor binding comounds

The present invention relates to compounds that bind to chemokine receptors, and having the formula wherein each A, X, Y, R1, R2 and R3 are substituents. The present invention also relates to methods of using such compounds, such as in treating HIV infection and inflammatory conditions such as rheumatoid arthritis. Furthermore, the present invention relates to methods to elevate progenitor and stem cell counts, as well as methods to elevate white blood cell counts, using such compounds.